Where does Medicinal Bioconvergence Research Center rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medicinal Bioconvergence Research Center ranks #16,186 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medicinal Bioconvergence Research Center hold?

Medicinal Bioconvergence Research Center holds 18 US utility patents granted between 2015 and 2023, spanning 12 technology areas.

What is Medicinal Bioconvergence Research Center's Innovation Score?

Medicinal Bioconvergence Research Center has an Innovation Score of 31.0 out of 100 (36th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medicinal Bioconvergence Research Center focus on?

Medicinal Bioconvergence Research Center's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 11 patents, ranking #1,740 of 6,058 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Medicinal Bioconvergence Research Center's patent grant rate increasing or decreasing?

Medicinal Bioconvergence Research Center's recent grant velocity is -36% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Medicinal Bioconvergence Research Center's patents?

Medicinal Bioconvergence Research Center's patents average 8.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medicinal Bioconvergence Research Center

Q: How is the Medicinal Bioconvergence Research Center patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 18 granted patents across 12 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medicinal ranks #16,186 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 12 technology areas.

#16,186
of 49,997 US assignees by volume: 36th percentile
by Innovation Score (31.0/100): 8.8
avg claims per patent: -36%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R16186 · Foreign Corporation #16,186 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #16,186/49,997
PHOTO-FINISH Manufacture…
CPC-FOCUS A61P · 12 areas
INNOV-THIN 31.0/100
CLAIMS-PAR 8.8 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -36% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Manufacture D'horlogerie Audemars Piguet SA (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Medicinal’s 31.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (33%) Velocity 3.3 pts (11%) Breadth 12.2 pts (39%) Claim depth 5.3 pts (17%)

Qualcomm Incorporated · highest

85
Medicinal Bioconverg… · this assignee

31
3D Lighting… · lowest

7

What this shows Medicinal's Innovation Score is 31.0/100 (36th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Medicinal?

Each dot is one of Medicinal’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Medicinal’s own 8.8 claims/patent is at or below the 10.3 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Medicinal vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Medicinal's grants concentrate

Medicinal Bioconvergence Research Center is a focused PatentsView assignee: 12 CPC subclasses with 61.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2015. By volume, Medicinal sits between Manufacture D'horlogerie Audemars Piguet SA and Metal-era, Inc..

Medicinal's three-year grant acceleration

Medicinal Bioconvergence Research Center shows 3 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Manufacture D'hor…

18
Mapal Fabrik für…

18
Match COM L L C

18
MEC

18
Melinta Therapeut…

18
Memory-tech Holdi…

18
Mercury Enterpris…

18
Metal-era

18
Medicinal Bioconv… ◀

18

What this shows Medicinal holds 18 patents at rank #16,176, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medicinal

By rank, the assignees closest to #16,176 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Medicinal's primary technology class.

Medicinal's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

31 36th percentile higher than 36% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Medicinal Bioconvergence Research Center patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	5.6%
2016	3	16.7%
2017	1	5.6%
2018	4	22.2%
2019	2	11.1%
2020	2	11.1%
2021	2	11.1%
2022	2	11.1%
2023	1	5.6%

Which technologies does Medicinal Bioconvergence Research Center patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C12Y - Enzymes 5

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 5

C07K - Peptides 3

C07D - Heterocyclic Compounds 3

G02B - Optical Elements, Systems OR Apparatus 2

A61B - DIAGNOSIS; SURGERY; Identification 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

Y02A - Technologies FOR Adaptation TO Climate Change 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Medicinal Bioconvergence Research Center's patent record in context - here's where to go next.

Medicinal Bioconvergence Research Center's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 61.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #16,186 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medicinal Bioconvergence Research Center against Manufacture D'horlogerie Audemars Piguet SA, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 31.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.